PDT Partners’s Astria Therapeutics ATXS Stock Holding History

PDT Partners’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-41,108	Closed	-$538K	–	532
2025 Q4	$538K	Sell	41,108 -13,534	-25%	-$162K	0.03%	417
2025 Q3	$398K	Hold	54,642	–	–	0.03%	476
2025 Q2	$293K	Buy	54,642 +25,935	+90%	+$126K	0.02%	601
2025 Q1	$153K	Buy	28,707 +18,200	+173%	+$127K	0.01%	692
2024 Q4	$93.9K	Sell	10,507 -2,242	-18%	-$23.8K	0.01%	691
2024 Q3	$140K	Buy	+12,749	New	+$142K	0.01%	678

PDT Partners's ATXS Position: Q1 2026 in Review

PDT Partners sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 41,108 shares — an estimated $538K sold.

PDT Partners first reported a position in ATXS in Q3 2024 and held it in 6 quarters. The position peaked at $538K in Q4 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

PDT Partners reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
PDT Partners sold 41,108 Astria Therapeutics shares in Q1 2026, an estimated $538K.
PDT Partners first reported a position in Astria Therapeutics in Q3 2024 and held it in 6 quarters.
PDT Partners's Astria Therapeutics position peaked at $538K in Q4 2025.
0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on PDT Partners's 13F filing for Q1 2026, filed 15 May 2026.